Weekly ReportApr 21–27, 2026
Anesthesiology, week 17 edition
We read 515 papers and selected 3.
Summary
This week’s anesthesiology literature emphasized perioperative organ protection, neuromodulation for pain, and large pragmatic trials that refine routine choices. A biomarker‑enriched KDIGO kidney‑protection bundle reduced moderate‑to‑severe AKI after major surgery; a large multinational pediatric RCT found no renal advantage of balanced crystalloids over saline; and mechanistic plus clinical data for transcutaneous auricular vagus nerve stimulation (taVNS) mapped a circuit and showed prevention of chronic postsurgical pain. These findings support targeted implementation of prevention bundles, cautious adoption of technologies informed by mechanism and RCTs, and system-level risk‑prediction approaches.
Selected Articles
1. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
In a pragmatic, multinational randomized trial across 47 emergency departments (n≈8,482 analyzed), balanced crystalloids did not reduce the composite major adverse kidney events at 30 days (MAKE30) compared with 0.9% saline in children with suspected septic shock. Hospital‑free days were similar, though balanced fluids produced lower rates of hyperchloremia and hypernatremia while hyperlactatemia was slightly more frequent.
Impact: Provides definitive, high‑quality evidence that balanced crystalloids do not reduce short‑term renal composite outcomes versus saline in pediatric septic shock, clarifying a major clinical question and informing fluid selection policies.
Clinical Implications: Either balanced fluids or 0.9% saline are reasonable for initial resuscitation in pediatric septic shock with attention to electrolyte profiles; balanced crystalloids may be preferred when avoiding hyperchloremia/hypernatremia is important, while monitoring lactate trends.
Key Findings
- MAKE30: 3.4% (balanced) vs 3.0% (saline); risk ratio 1.10 (95% CI 0.88–1.40; P=0.85).
- Median hospital‑free days (28‑day window) identical (median 23).
- Electrolyte differences: hyperchloremia 31.4% (balanced) vs 49.0% (saline); hypernatremia 1.8% vs 3.1%; hyperlactatemia 19.8% vs 16.7%.
2. Auricular vagus nerve stimulation drives analgesia via an auricle-brain axis in a mouse model of neuropathic pain.
Preclinical multimodal experiments map an auricle‑to‑brain circuit (jugular‑nodose ganglia → NTS pro‑opiomelanocortinergic neurons → vlPAG glutamatergic neurons) mediating taVNS analgesia in neuropathic pain mice; optogenetic activation recapitulates and chemogenetic silencing abolishes effect. The work provides causal circuit evidence to guide translational parameter optimization for taVNS.
Impact: Provides first‑class mechanistic, causal circuit mapping for taVNS analgesia—an essential translational step that rationalizes electrode placement, targets, and biomarkers to advance human trials.
Clinical Implications: Although preclinical, the identified JNG→NTS→vlPAG axis supports targeted taVNS parameter exploration in early human trials for perioperative and neuropathic pain, and suggests candidate biomarkers (brainstem/PAG engagement) for responder stratification.
Key Findings
- taVNS produces robust analgesia in a neuropathic pain mouse model.
- Identified circuit: jugular‑nodose ganglia → NTS (POMC neurons) → vlPAG glutamatergic neurons.
- Optogenetic activation at multiple nodes mimics taVNS analgesia; chemogenetic silencing abolishes it.
3. Implementation of a kidney protection strategy to prevent acute kidney injury after major surgery in high-risk patients identified by biomarkers: a systematic review and individual participant data meta-analysis of randomized controlled trials.
An IPD meta‑analysis pooling four RCTs (n=1,851) found that a KDIGO‑based kidney protection bundle applied to biomarker‑enriched high‑risk surgical patients reduced moderate‑to‑severe AKI within 72 hours (KDIGO stage ≥2; OR 0.55, 95% CI 0.44–0.70) without heterogeneity. The bundle combined hemodynamic and fluid optimization, nephrotoxin avoidance, frequent renal monitoring, and glycemic control.
Impact: High‑level IPD evidence that a standardized perioperative kidney protection bundle prevents clinically meaningful AKI in biomarker‑identified high‑risk patients, offering an implementable strategy to reduce postoperative kidney injury.
Clinical Implications: Integrate KDIGO‑based kidney protection bundles into perioperative pathways for biomarker‑identified high‑risk patients (hemodynamic targets, nephrotoxin stewardship, frequent renal labs, glucose control) and prioritize pragmatic multicenter implementation studies.
Key Findings
- KDIGO stage ≥2 AKI within 72 h reduced with bundle: OR 0.55 (95% CI 0.44–0.70; p<0.0001).
- No statistical heterogeneity across included trials.
- Bundle components: hemodynamic/fluid optimization, nephrotoxin avoidance, renal monitoring, glycemic control.